
Photo taken from Eric K. Singhi/X
Feb 28, 2024, 12:09
Eric K. Singhi: Patrick Forde discusses the nuanced choices thoracic medical oncologists and patients with early-stage Non-small-cell lung cancer (NSCLC) are facing in clinics today
Eric K. Singhi, Thoracic Medical Oncologist and Assistant Professor at the MD Anderson Cancer Center, recently shared a post on X/Twitter:
“Neoadjuvant, adjuvant, or both? Patrick Forde discusses the nuanced choices thoracic medical oncologists and patients with early-stage Non-small-cell lung cancer (NSCLC) are facing in clinics today.”
Source: Eric K. Singhi/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 22, 2025, 05:18
Feb 22, 2025, 05:15
Feb 22, 2025, 05:05
Feb 22, 2025, 04:54
Feb 22, 2025, 04:49
Feb 22, 2025, 04:33
Feb 22, 2025, 04:29